On September 8, 2026, VINPHACO co-organised its Speaker Tour at Ninh Binh Obstetrics and Paediatrics Hospital. The programme focused on obstetric safety, regional anaesthesia and postpartum haemorrhage management, bringing together healthcare professionals to discuss important clinical topics in maternal care.<\/p>\n
For international pharmaceutical partners, understanding a manufacturer’s product portfolio, manufacturing capabilities and engagement with the healthcare sector can provide useful context when evaluating potential business cooperation.<\/p>\n
VINPHACO’s Speaker Tour forms part of its broader engagement with the Vietnamese healthcare community across multiple medical specialties.<\/p>\n
Table of Contents<\/h3>\n\n- VINPHACO Speaker Tour<\/a> in Ninh Binh<\/li>\n
- Clinical Expertise in Obstetric Safety and Maternal Care<\/li>\n
- Why Postpartum Haemorrhage Matters<\/li>\n
- Connecting Clinical Education with Pharmaceutical Manufacturing<\/li>\n
- VINPHACO’s Pharmaceutical Manufacturing and International Presence<\/li>\n
- Building Long-Term Engagement with Healthcare Professionals<\/li>\n<\/ul>\n
VINPHACO Speaker Tour in Ninh Binh<\/h3>\n
![\"Conference](\"https:\/\/vinphaco.net\/wp-content\/uploads\/2026\/10\/11-640x427.jpg\")
<\/p>\n
The Ninh Binh edition of the VINPHACO Speaker Tour took place on September 8, 2026, at Ninh Binh Obstetrics and Paediatrics Hospital.<\/p>\n
According to the event information provided, the programme attracted approximately 250 healthcare professionals from across the region.<\/p>\n
The session was chaired by Senior Specialist II Dr. Pham Van Dau, Director of Ninh Binh Obstetrics and Paediatrics Hospital, and Senior Specialist II Dr. Pham Ngoc Ha, Deputy Director of the hospital.<\/p>\n
The scientific programme addressed two important areas of maternal healthcare: regional anaesthesia in obstetric practice and the management of postpartum haemorrhage.<\/p>\n
Vinphaco- Medicine manufacturer Vietnam bringing specialist knowledge into a regional hospital setting, the programme provided a forum for healthcare professionals to exchange clinical perspectives and discuss issues relevant to obstetric care. medicine manufacturer Vietnam<\/p>\n
Clinical Expertise in Obstetric Safety and Maternal Care<\/h3>\n
![\"Presentation](\"https:\/\/vinphaco.net\/wp-content\/uploads\/2026\/10\/8-640x404.jpg\")
<\/p>\n
The programme featured three speakers with academic and clinical backgrounds in anaesthesia, obstetrics and gynaecology.<\/p>\n
Dr. Do Van Loi, PhD, was identified in the event information as Vice President of the Vietnam Obstetric Anaesthesia Society and Director of the Anaesthesia and Resuscitation Centre at Phenikaa Hospital.<\/p>\n
His session focused on regional anaesthesia in obstetric settings, an area of clinical practice in which appropriate technique selection, patient assessment and monitoring are important considerations.<\/p>\n
Dr. Nguyen Thai Giang, PhD, was listed as a lecturer in the Department of Obstetrics and Gynaecology at Hanoi Medical University and Deputy Head of the Gynaecological Oncology Department at the National Obstetrics Hospital.<\/p>\n
His contribution addressed postpartum haemorrhage management, a critical subject in maternal healthcare.<\/p>\n
Senior Specialist II Dr. Tran Quang Khai, Head of the Delivery Department at Ninh Binh Obstetrics and Paediatrics Hospital, contributed the perspective of local clinical practice.<\/p>\n
Together, the programme’s themes connected specialist knowledge with the practical requirements of obstetric services.<\/p>\n
Note: Speaker names, professional titles and affiliations should be checked against the final event programme before publication.<\/em><\/p>\nWhy Postpartum Haemorrhage Matters<\/h3>\n
![\"medicine](\"https:\/\/vinphaco.net\/wp-content\/uploads\/2026\/10\/5-640x367.jpg\")
<\/p>\n
Postpartum haemorrhage (PPH), or excessive bleeding after childbirth, remains a major global maternal health challenge.<\/p>\n
The World Health Organization (WHO) identifies haemorrhage as a leading cause of maternal mortality. Its 2025 consolidated guidelines on postpartum haemorrhage emphasise the importance of effective prevention, timely diagnosis and appropriate treatment.<\/p>\n
Clinical management depends on multiple factors, including early recognition, prompt intervention, trained healthcare personnel and access to appropriate medicines and supportive care.<\/p>\n
Uterotonic medicines have an important role in preventing or managing postpartum bleeding when used in accordance with applicable clinical guidelines and treatment protocols. The selection and use of medicines must be determined by qualified healthcare professionals in the relevant clinical context.<\/p>\n
These considerations illustrate why maternal healthcare requires coordinated efforts across clinical practice, healthcare systems and pharmaceutical supply chains.<\/p>\n
For pharmaceutical manufacturers and international healthcare partners, the availability of appropriate medicines is one part of a broader effort to support safe and effective patient care.<\/p>\n
Reference:<\/strong> WHO \u2014 Consolidated guidelines for the prevention, diagnosis and treatment of postpartum haemorrhage<\/p>\nConnecting Clinical Education with Pharmaceutical Manufacturing<\/h3>\n
![\"Conference](\"https:\/\/vinphaco.net\/wp-content\/uploads\/2026\/10\/12-640x455.jpg\")
<\/p>\n
Pharmaceutical manufacturing and clinical practice operate in different parts of the healthcare system, but they are connected by the medicines used in patient care.<\/p>\n
Clinical education programmes provide opportunities for healthcare professionals to discuss current practice, share experience and strengthen professional knowledge.<\/p>\n
For pharmaceutical manufacturers, engagement with the healthcare community can also provide a broader understanding of therapeutic settings, professional expectations and the practical context in which medicines are used.<\/p>\n
However, clinical education and manufacturing quality serve distinct purposes. Participation in a scientific programme should not, by itself, be interpreted as evidence of a product’s clinical performance, regulatory approval or manufacturing quality.<\/p>\n
These aspects require their own supporting evidence, including relevant quality documentation, regulatory assessments and appropriate clinical data where applicable.<\/p>\n
VINPHACO’s Speaker Tour represents one form of engagement with healthcare professionals. Its significance lies in the opportunity to bring professionals together around clinical topics relevant to their work.<\/p>\n
VINPHACO’s Pharmaceutical Manufacturing and International Presence<\/h3>\n
VINPHACO Speaker Tour in Ninh Binh<\/h3>\n
<\/p>\n
The Ninh Binh edition of the VINPHACO Speaker Tour took place on September 8, 2026, at Ninh Binh Obstetrics and Paediatrics Hospital.<\/p>\n
According to the event information provided, the programme attracted approximately 250 healthcare professionals from across the region.<\/p>\n
The session was chaired by Senior Specialist II Dr. Pham Van Dau, Director of Ninh Binh Obstetrics and Paediatrics Hospital, and Senior Specialist II Dr. Pham Ngoc Ha, Deputy Director of the hospital.<\/p>\n
The scientific programme addressed two important areas of maternal healthcare: regional anaesthesia in obstetric practice and the management of postpartum haemorrhage.<\/p>\n
Vinphaco- Medicine manufacturer Vietnam bringing specialist knowledge into a regional hospital setting, the programme provided a forum for healthcare professionals to exchange clinical perspectives and discuss issues relevant to obstetric care. medicine manufacturer Vietnam<\/p>\n
Clinical Expertise in Obstetric Safety and Maternal Care<\/h3>\n
<\/p>\n
The programme featured three speakers with academic and clinical backgrounds in anaesthesia, obstetrics and gynaecology.<\/p>\n
Dr. Do Van Loi, PhD, was identified in the event information as Vice President of the Vietnam Obstetric Anaesthesia Society and Director of the Anaesthesia and Resuscitation Centre at Phenikaa Hospital.<\/p>\n
His session focused on regional anaesthesia in obstetric settings, an area of clinical practice in which appropriate technique selection, patient assessment and monitoring are important considerations.<\/p>\n
Dr. Nguyen Thai Giang, PhD, was listed as a lecturer in the Department of Obstetrics and Gynaecology at Hanoi Medical University and Deputy Head of the Gynaecological Oncology Department at the National Obstetrics Hospital.<\/p>\n
His contribution addressed postpartum haemorrhage management, a critical subject in maternal healthcare.<\/p>\n
Senior Specialist II Dr. Tran Quang Khai, Head of the Delivery Department at Ninh Binh Obstetrics and Paediatrics Hospital, contributed the perspective of local clinical practice.<\/p>\n
Together, the programme’s themes connected specialist knowledge with the practical requirements of obstetric services.<\/p>\n
Note: Speaker names, professional titles and affiliations should be checked against the final event programme before publication.<\/em><\/p>\n Postpartum haemorrhage (PPH), or excessive bleeding after childbirth, remains a major global maternal health challenge.<\/p>\n The World Health Organization (WHO) identifies haemorrhage as a leading cause of maternal mortality. Its 2025 consolidated guidelines on postpartum haemorrhage emphasise the importance of effective prevention, timely diagnosis and appropriate treatment.<\/p>\n Clinical management depends on multiple factors, including early recognition, prompt intervention, trained healthcare personnel and access to appropriate medicines and supportive care.<\/p>\n Uterotonic medicines have an important role in preventing or managing postpartum bleeding when used in accordance with applicable clinical guidelines and treatment protocols. The selection and use of medicines must be determined by qualified healthcare professionals in the relevant clinical context.<\/p>\n These considerations illustrate why maternal healthcare requires coordinated efforts across clinical practice, healthcare systems and pharmaceutical supply chains.<\/p>\n For pharmaceutical manufacturers and international healthcare partners, the availability of appropriate medicines is one part of a broader effort to support safe and effective patient care.<\/p>\n Reference:<\/strong> WHO \u2014 Consolidated guidelines for the prevention, diagnosis and treatment of postpartum haemorrhage<\/p>\n Pharmaceutical manufacturing and clinical practice operate in different parts of the healthcare system, but they are connected by the medicines used in patient care.<\/p>\n Clinical education programmes provide opportunities for healthcare professionals to discuss current practice, share experience and strengthen professional knowledge.<\/p>\n For pharmaceutical manufacturers, engagement with the healthcare community can also provide a broader understanding of therapeutic settings, professional expectations and the practical context in which medicines are used.<\/p>\n However, clinical education and manufacturing quality serve distinct purposes. Participation in a scientific programme should not, by itself, be interpreted as evidence of a product’s clinical performance, regulatory approval or manufacturing quality.<\/p>\n These aspects require their own supporting evidence, including relevant quality documentation, regulatory assessments and appropriate clinical data where applicable.<\/p>\n VINPHACO’s Speaker Tour represents one form of engagement with healthcare professionals. Its significance lies in the opportunity to bring professionals together around clinical topics relevant to their work.<\/p>\nWhy Postpartum Haemorrhage Matters<\/h3>\n
<\/p>\nConnecting Clinical Education with Pharmaceutical Manufacturing<\/h3>\n
<\/p>\nVINPHACO’s Pharmaceutical Manufacturing and International Presence<\/h3>\n